Dr. Jeffrey Victor Matous, MD

Dr. Matous practices at HealthONE Clinic Services - Oncology Hematology in Denver, Colorado.

Dr. Matous' NPI, 1992789036, was assigned on December 2, 2005. Dr. Matous graduated from University Of Washington School Of Medicine in 1985. Dr. Matous holds Colorado license 28753.

Dr. Matous' primary practice is HealthONE Clinic Services - Oncology Hematology, at 1721 E 19th Ave, Denver, CO 80218 in Denver County. The practice phone is (720) 754-4800.

Dr. Matous' primary practice is HealthONE Clinic Services - Oncology Hematology in Denver, Colorado. Dr. Matous is also affiliated with HCA HealthONE Presbyterian St. Luke's. The medical group on file is HCA HealthONE Physicians. Dmand AI also links Dr. Matous to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Matous practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Matous' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Matous is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Matous' licenses on file in 3 states: Colorado, Montana and Nebraska.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lymphoma, multiple myeloma, neutropenia and prostate cancer among the conditions Dr. Matous treats.

CMS data shows 14,181 Medicare services from Dr. Matous across 20 procedure codes in 2024, for 342 Medicare patients. Medicare paid $388,202 for them. Every service was in an office.

CMS counts 342 Medicare patients who saw Dr. Matous in 2024. The largest group is 65 to 74, with 184 patients. 67% of them have high cholesterol, and 66% have high blood pressure. 5% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Matous' median patient age at 70, with 44% women.

In 2024, Dr. Matous wrote 688 Medicare Part D claims for 109 patients. 69% of them were for generic drugs. CMS names the drug for 503 of them, across 17 drugs with 11 or more claims each, at $2,391,775 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Matous for performance year 2024, reported individually. Dr. Matous accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Matous as offering telehealth.

Dmand AI links 48 papers to Dr. Matous, published from 2010 to 2025. 2016 was the busiest year, with 3. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Brentuximab Vedotin. Dr. Matous has published most often in Blood. Dr. Matous' most frequent co-authors are Ajay Kumar Gopal, Ranjana Advani, MD and Nancy Lee Bartlett, MD.

Dmand AI links Dr. Matous to 17 clinical trials, 7 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Blood Protein Disorders, Multiple Myeloma and Immunoglobulin Light-chain Amyloidosis. Colorado Blood Cancer Institute sponsors the most, 3.

CMS Open Payments shows 39 general payments to Dr. Matous from 13 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $553. It also lists 2 research payments totaling $11,207 in 2024.

Dr. Matous graduated from University Of Washington School Of Medicine in 1985. Dr. Matous is a member of ASCO.

Dr. Matous is in network with 17 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.